Over the past years, the number of mobile phone subscribers in China has been increasing at an exponential rate. By the end of 2015, there was approximately 202.47 million cell phones produced in China1 along with 1,033.6 million mobile users registered in China, with the number of users expected to grow to 1,086.8 by 2019. […]
Read More
Over the last 10 years, South Korea has increasingly become a global clinical trial (CT) hub and has established itself as one of the leading CT destinations in the Asia region. In 2015, South Korea approved a total of 675 trials from South Korean and multinational drug makers for early phase studies that would lead […]
Read More
EDC has become the data management platform of choice around the world, offering advantages such as increasing the quality and timely collection of data. Medrio, an EDC company that offers eClinical software solutions, has quoted that 70% of clinical trials are using EDC as a forms of collecting data in the United States. In China, […]
Read More
Access to large markets where clinical trials that can investigate real patient needs, and do so in a rapid fashion, is invaluable for clinical research organisations. One such example of George Clinical rapid and access to huge markets took place in China, where diabetes patients numbered up to 90 million in 2010, and the most […]
Read More
BEIJING – October 15, 2016 – George Clinical welcomes the establishment of the Heart Health Research Center, a collaborative initiative developed by Cardio Union, an emerging multi-disciplinary healthcare organization and George Clinical’s partner in research, The George Institute for Global Health. The Heart Health Research Center (HHRC) will help to address the growing burden of […]
Read More
George Clinical welcomes the development of the INVICTUS program which was launched at the World Heart Federation’s World Congress of Cardiology and Cardiovascular Health recently. The study, supported by Bayer AG and endorsed by the World Heart Federation, will be conducted by George Clinical in China and reinforces the importance of scientific leadership when undertaking […]
Read More
Philip Gregory of George Clinical focuses on China, in a three part series originally published on http://innovations.bbkworldwide.com/part-iii-chinas-future-in-global-clinical-research that discusses developments in the clinical trial landscape of East Asia and Japan. Active international collaboration has facilitated the rise of the Asia-Pacific region in global clinical research. With the world’s largest population, China’s recent changes to their clinical trial processes and […]
Read MoreIn a surprise move, the State Council in China has recently released a directive announcing its view on reforming the drug and medical device review and approval process in China. The State Council oversees the Chinese Food and Drug Administration (CFDA), and it is noteworthy that these changes were announced at a high level, reflecting […]
Read MoreGeorge Clinical in China recently celebrated its second anniversary as an independent entity in China. Although George Clinical has been conducting Phase 11 to Phase IV studies in China for over 8 years, previously it was incorporated into The George Institute in China – but now operates as a separate legal entity. The last two […]
Read More
